MQCC confirms microarray reliability
This article was originally published in The Gray Sheet
First report of the Microarray Quality Control Consortium, published in the Sept. 8 Nature Biotechnology, concludes that under the appropriate circumstances, "microarray data can indeed be reproducible and comparable among different formats and laboratories." The consortium, spearheaded by FDA scientists, assessed the performance of seven microarray platforms in profiling RNA expression. Published reports question the reliability of the tests, which are used to detect the cellular activity of DNA and RNA. FDA's National Center for Toxicological Research will hold a meeting on microarrays in Jefferson, Ark. on Sept. 21...
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.